SMARCA4 and neoplasm: We evaluated the expression of SMARCA4 among the cancers of unknown primary and identified a significantly lower expression of SMARCA4 in tumours with biallelic LOF mutations compared to WT (p = 0.54 × 10−2; Figure 6k).